Literature DB >> 24613042

Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation.

Takehiro Kimura1, Seiji Takatsuki2, Kohei Inagawa2, Yoshinori Katsumata2, Takahiko Nishiyama2, Nobuhiro Nishiyama2, Kotaro Fukumoto2, Yoshiyasu Aizawa2, Yoko Tanimoto2, Kojiro Tanimoto2, Keiichi Fukuda2.   

Abstract

BACKGROUND: We investigated various serum inflammatory markers to predict ablation responders who have no atrial fibrillation (AF) relapse after the initial ablation.
METHODS: Forty-four consecutive AF patients (age: 59 ± 8 years, paroxysmal: 31, CHADS₂: 1.1 ± 1.1) who underwent an initial pulmonary vein isolation were investigated. Various serum inflammatory markers, such as adiponectin, ANP, BNP, 1CTP, F1+2, hs-CRP, IL-6, intact P1NP, MDA-LDL, MMP-2, TGF-β, TIMP-2, and TNF-α, were evaluated prior to ablation. AF relapse was defined as AF documented in telemonitoring electrocardiograms twice a day during 9.7 ± 2.4 months of follow-up with three months of a blanking-period.
RESULTS: A total of 29 patients (paroxysmal: 21) maintained sinus rhythm after the initial catheter ablation. These ablation responders had significantly lower MMP-2 (Sinus vs. Relapsed: 748 ± 132.7 vs. 841.2 ± 152.4 ng/mL, P=0.042) and TNF-α (1.1 ± 0.4 vs. 1.8 ± 1.7 pg/mL, P=0.046) levels prior to ablation. A BNP-adjusted Cox multivariate regression analysis revealed that the independent predictive factor for AF recurrence was high MMP-2 levels (>766 ng/mL) accompanied by high TNF-α levels (>1.2 pg/mL).
CONCLUSIONS: The levels of MMP-2 and TNF-α might be useful for predicting initial AF catheter ablation responders.
Copyright © 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Follow-up, inflammation; Matrix metalloproteinase-2; Tumour necrosis factor-α

Mesh:

Substances:

Year:  2014        PMID: 24613042     DOI: 10.1016/j.hlc.2014.02.003

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  15 in total

Review 1.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

Review 2.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

3.  Blood lipid levels and recurrence of atrial fibrillation after radiofrequency catheter ablation: a prospective study.

Authors:  Yunpeng Shang; Nan Chen; Qiqi Wang; Chengui Zhuo; Jianqiang Zhao; Ning Lv; Yuan Huang
Journal:  J Interv Card Electrophysiol       Date:  2019-04-07       Impact factor: 1.900

4.  Markers of Inflammation, Oxidative Stress, and Fibrosis in Patients with Atrial Fibrillation.

Authors:  Priit Pauklin; Mihkel Zilmer; Jaan Eha; Kaspar Tootsi; Mart Kals; Priit Kampus
Journal:  Oxid Med Cell Longev       Date:  2022-05-23       Impact factor: 7.310

5.  Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.

Authors:  Chunxia Yao; Tina Veleva; Larry Scott; Shuyi Cao; Luge Li; Gong Chen; Prince Jeyabal; Xiaolu Pan; Katherina M Alsina; Issam Abu-Taha; Shokoufeh Ghezelbash; Corey L Reynolds; Ying H Shen; Scott A LeMaire; Wilhelm Schmitz; Frank U Müller; Ali El-Armouche; N Tony Eissa; Christine Beeton; Stanley Nattel; Xander H T Wehrens; Dobromir Dobrev; Na Li
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

6.  Association of Plasma Transforming Growth Factor-β1 Levels and the Risk of Atrial Fibrillation: A Meta-Analysis.

Authors:  Jiao Li; Yajuan Yang; Chee Yuan Ng; Zhiwei Zhang; Tong Liu; Guangping Li
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

7.  Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study.

Authors:  Gordon A Begg; Rashed Karim; Tobias Oesterlein; Lee N Graham; Andrew J Hogarth; Stephen P Page; Christopher B Pepper; Kawal Rhode; Gregory Y H Lip; Arun V Holden; Sven Plein; Muzahir H Tayebjee
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

8.  Routine 18F-FDG PET/CT does not detect inflammation in the left atrium in patients with atrial fibrillation.

Authors:  Nemanja Avramovic; Lars Eckardt; Christian Wenning; Philipp S Lange; Gerrit Frommeyer; Kristina Wasmer; Christian Pott
Journal:  Int J Cardiovasc Imaging       Date:  2017-02-22       Impact factor: 2.357

9.  Multiple biomarkers and arrhythmia outcome following catheter ablation of atrial fibrillation: The Guangzhou Atrial Fibrillation Project.

Authors:  Hai Deng; Alena Shantsila; Pi Guo; Xianzhang Zhan; Xianhong Fang; Hongtao Liao; Yang Liu; Wei Wei; Lu Fu; Shulin Wu; Yumei Xue; Gregory Y H Lip
Journal:  J Arrhythm       Date:  2018-08-31

10.  Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation.

Authors:  Gordon A Begg; Peter P Swoboda; Rashed Karim; Tobias Oesterlein; Kawal Rhode; Arun V Holden; John P Greenwood; Eduard Shantsila; Gregory Y H Lip; Sven Plein; Muzahir H Tayebjee
Journal:  J Cardiovasc Magn Reson       Date:  2020-02-10       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.